We hypothesized that the interruption of MAPK signaling with selumetinib in KRAS-transformed tumor cells would decrease the production of TGF-α and prevent the secondary activation of the EGFR downstream signaling pathways, a known resistance mechanism following the inhibition of mutant Ras (19). This evidence concerns the gene TGFA and neoplasm.